Thyroid Lobectomy Is Associated with Excellent Clinical Outcomes in Properly Selected Differentiated Thyroid Cancer Patients with Primary Tumors Greater Than 1 cm

被引:46
|
作者
Vaisman, Fernanda [1 ,2 ]
Momesso, Denise
Bulzico, Daniel A. [2 ]
Pessoa, Cencita H. C. N. [2 ]
Gonalves da Cruz, Manuel Domingos [3 ]
Dias, Fernando [4 ]
Corbo, Rossana [2 ]
Vaisman, Mario
Michael Tuttle, R. [5 ]
机构
[1] Univ Fed Rio Janeiro, Serv Endocrinol, Rua Rodolpho Paulo Rocco 255, BR-21941913 Rio De Janeiro, RJ, Brazil
[2] Inst Nacl Canc, Centro, Endocrinol Ser, Praca,Cruz Vermelha 23, BR-20230130 Rio De Janeiro, RJ, Brazil
[3] Univ Fed Rio Janeiro, Surg Serv, Rua Rodolpho Paulo Rocco 255, BR-21941913 Rio De Janeiro, RJ, Brazil
[4] Inst Nacl Canc, Centro, Head & Neck Serv, BR-20230130 Rio De Janeiro, RJ, Brazil
[5] Mem Sloan Kettering Canc Ctr, Serv Endocrinol, 1275 York Ave, New York, NY 10065 USA
关键词
D O I
10.1155/2013/398194
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objective. An individualized risk-based approach to the treatment of thyroid cancer is being extensively discussed in the recent literature. However, controversies about the ideal surgical approach remain an important issue with regard to the impact on prognosis and follow-up strategies. This study was designed to describe clinical outcomes in a cohort of low and intermediate risk thyroid cancer patients treated with thyroid lobectomy. Methods. Retrospective review of 70 patients who underwent lobectomy. Results. After a median follow-up of 11 years, 5 patients (5/70, 7.1%) recurred and 5 had a completion for benign lesions, while 60 patients (86%) continued to be observed without evidence for disease recurrence. Suspicious ultrasound findings were significantly more common in patients that had structural disease recurrence (100% versus 4.3%, p < 0.001). Furthermore, a rising suppressed Tg value over time was also associated with structural disease recurrence (80% versus 21.5%, p = 0.01). After additional therapy, 99% of the patients had no evidence of disease. Conclusions. Properly selected thyroid cancer patients can be treated with lobectomy with excellent clinical outcomes.
引用
收藏
页数:5
相关论文
共 50 条
  • [1] Controversy: For or against thyroid lobectomy in &gt; 1 cm differentiated thyroid cancer?
    Menegaux, Fabrice
    Lifante, Jean-Christophe
    ANNALES D ENDOCRINOLOGIE, 2021, 82 (02) : 78 - 82
  • [2] Thyroid lobectomy in patients with differentiated thyroid cancer: an analysis of the clinical outcomes in a nationwide multicenter study
    Diez, Juan J.
    Alcazar, Victoria
    Iglesias, Pedro
    Romero-Lluch, Ana
    Sastre, Julia
    Perez Corral, Begona
    Zafon, Carles
    Carlos Galofre, Juan
    Jose Pamplona, Maria
    GLAND SURGERY, 2021, 10 (02) : 678 - +
  • [3] Use of Radioiodine after Thyroid Lobectomy in Patients with Differentiated Thyroid Cancer: Does It Change Outcomes?
    Kiernan, Colleen M.
    Parikh, Alexander A.
    Parks, Lee L.
    Solorzano, Carmen C.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2015, 220 (04) : 617 - 625
  • [4] Characteristics of contralateral carcinomas in patients with differentiated thyroid cancer larger than 1 cm
    Lutske Lodewijk
    Wouter P. Kluijfhout
    Jakob W. Kist
    Inge Stegeman
    John T. M. Plukker
    Els J. Nieveen van Dijkum
    H. Jaap Bonjer
    Nicole D. Bouvy
    Abbey Schepers
    Johannes H. W. de Wilt
    Romana T. Netea-Maier
    Jos A. van der Hage
    Jacobus W. A. Burger
    Gavin Ho
    Wayne S. Lee
    Wen T. Shen
    Anna Aronova
    Rasa Zarnegar
    Cassandre Benay
    Elliot J. Mitmaker
    Mark S. Sywak
    Ahmad M. Aniss
    Schelto Kruijff
    Benjamin James
    Raymon H. Grogan
    Laurent Brunaud
    Guillaume Hoch
    Chiara Pandolfi
    Daniel T. Ruan
    Michael D. Jones
    Marlon A. Guerrero
    Gerlof D. Valk
    Inne H. M. Borel Rinkes
    Menno R. Vriens
    Langenbeck's Archives of Surgery, 2016, 401 : 365 - 373
  • [5] Characteristics of contralateral carcinomas in patients with differentiated thyroid cancer larger than 1 cm
    Lodewijk, Lutske
    Kluijfhout, Wouter P.
    Kist, Jakob W.
    Stegeman, Inge
    Plukker, John T. M.
    van Dijkum, Els J. Nieveen
    Bonjer, H. Jaap
    Bouvy, Nicole D.
    Schepers, Abbey
    de Wilt, Johannes H. W.
    Netea-Maier, Romana T.
    van der Hage, Jos A.
    Burger, Jacobus W. A.
    Ho, Gavin
    Lee, Wayne S.
    Shen, Wen T.
    Aronova, Anna
    Zarnegar, Rasa
    Benay, Cassandre
    Mitmaker, Elliot J.
    Sywak, Mark S.
    Aniss, Ahmad M.
    Kruijff, Schelto
    James, Benjamin
    Grogan, Raymon H.
    Brunaud, Laurent
    Hoch, Guillaume
    Pandolfi, Chiara
    Ruan, Daniel T.
    Jones, Michael D.
    Guerrero, Marlon A.
    Valk, Gerlof D.
    Rinkes, Inne H. M. Borel
    Vriens, Menno R.
    LANGENBECKS ARCHIVES OF SURGERY, 2016, 401 (03) : 365 - 373
  • [6] Use of Radioiodine after Thyroid Lobectomy in Patients with Differentiated Thyroid Cancer: Does It Change Outcomes? Discussion
    Perrier, Nancy
    Snyder, Samuel
    Carneiro-Pla, Denise M.
    Rosen, Jennifer
    Kiernan, Colleen M.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2015, 220 (04) : 625 - 627
  • [7] Outcomes of Patients With Metastatic Differentiated Thyroid Cancer After Excellent Response to Treatment
    Hsu, Chia-Jung
    Lai, Kun-Yu
    Lu, Yu-Ling
    Wu, Ming-Hsien
    Liu, Feng-Hsuan
    Lin, Shu-Fu
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [8] Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer
    Vaisman, F.
    Shaha, A.
    Fish, S.
    Tuttle, R. Michael
    CLINICAL ENDOCRINOLOGY, 2011, 75 (01) : 112 - 119
  • [9] Exploring the Susceptibility to Multiple Primary Tumors in Patients with Differentiated Thyroid Cancer
    Valerio, Laura
    Cantara, Silvia
    Mattii, Elisa
    Dalmiglio, Cristina
    Sagnella, Alfonso
    Salvemini, Antonia
    Cartocci, Alessandra
    Maino, Fabio
    Castagna, Maria Grazia
    DIAGNOSTICS, 2024, 14 (12)
  • [10] The Frequency of Differentiated Thyroid Cancer Recurrence in 2302 Patients With Excellent Response to Primary Therapy
    Palyga, Iwona
    Rumian, Maciej
    Kosel, Alicja
    Albrzykowski, Maciej
    Krawczyk, Paulina
    Kalwat, Agata
    Gasior-Perczak, Danuta
    Walczyk, Agnieszka
    Kuchareczko, Artur
    Kopczynski, Janusz
    Chrapek, Magdalena
    Gozdz, Stanislaw
    Kowalska, Aldona
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024, 109 (02): : e569 - e578